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Objective. Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis of medium-sized visceral vessels. However, cuta-
neous arteritis (CA) and gastrointestinal (GI) vasculitis are forms of single-organ vasculitis having indistinguishable histo-
pathologic findings from PAN. The aim of this study was to evaluate and compare the clinical characteristics, treatment,
and outcomes of patients with systemic PAN, CA, and GI vasculitis.
Methods. Retrospective cohorts were assembled, consisting of patients with PAN, CA, and GI vasculitis between 1980 and
2014. The demographics, clinical characteristics, treatment, and outcomes of patients were abstracted from medical records.
Results. We included 48 patients with PAN, 41 patients with CA, and 19 patients with GI vasculitis. The disease of 1 patient
evolved from CA to systemic PAN during the disease course. At diagnosis, 94% of patients with PAN, 93% of patients with CA,
and 67% of patients with GI vasculitis were treated with glucocorticoids. Additional immunosuppressive agents were used in
67% of PAN, 37% of GI vasculitis, and 32% of CA cases. The 5-year cumulative relapse rate was 45.2% in CA, and only 9.6%
in PAN during a followup of approximately 6 years. No deaths were observed in the CA group. The survival rate at 10 years
was 66% in the PAN group and 61% in the GI vasculitis group.
Conclusion. Systemic PAN, CA, and GI vasculitis take different clinical courses and therefore may be different diseases, rather
than existing on a spectrum of the same disease. Progression of CA to systemic PAN is very rare. Relapse risk is low during fol-
lowup in PAN. Patients with CA have a higher relapse rate than those with systemic PAN, possibly due to less use of immuno-
suppressive therapy in CA.
INTRODUCTION
Polyarteritis nodosa (PAN) is a rare systemic necrotizing vas-
culitis predominantly affecting medium-sized visceral arter-
ies and their branches, with an estimated annual incidence
of 2–9 per 1 million adults (1,2). Skin and peripheral nervous
system manifestations are the most common clinical
findings, and glomerulonephritis is typically absent (3). Gas-
trointestinal manifestations are also frequently seen and are
among the most important predictors of morbidity and mor-
tality (4). A form of PAN limited to the skin, with no sys-
temic involvement, was first defined as cutaneous PAN by
Lindberg (5). To date, the progression of cutaneous PAN to
systemic PAN has been rarely reported (6).
Vasculitic involvement of the gastrointestinal (GI) sys-
tem is a well-known manifestation of small- and medium-
sized vessel vasculitides. It is common in PAN, anti-
neutrophil cytoplasmic antibody (ANCA)–associated vas-
culitis (AAV), and IgA vasculitis (7,8). The presence of GI
manifestations in systemic vasculitis is associated with a
worse prognosis (9). Vasculitis limited to the GI system is
rarely observed as a form of single-organ vasculitis (SOV),
and is also associated with significant morbidity and mor-
tality (10). Histopathologic and angiographic findings of
necrotizing vasculitis limited to the GI system cannot be
distinguished from PAN.
The revised 2012 International Chapel Hill Consensus
Conference (CHCC) on the Nomenclature of Vasculitides
includes additional categories of vasculitis, such as SOV
and vasculitis associated with probable etiology. SOV was
defined as a vasculitis affecting any size artery and/or vein
in a single organ with no systemic manifestations. Follow-
ing the CHCC on nomenclature, cutaneous PAN was
termed cutaneous arteritis (CA), a form of SOV. PAN is
now divided according to etiology, with hepatitis B virus
(HBV)–associated PAN considered separately from idio-
pathic systemic PAN (1).
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Even though the clinical characteristics and outcomes of
these conditions have been reported separately, there are
no studies that have directly compared PAN, CA, and GI
vasculitis. The aim of this study was to evaluate and com-
pare the clinical characteristics, treatment, and outcomes
of patients with systemic PAN, CA, and GI vasculitis.
PATIENTS AND METHODS
Patient population. A retrospective cohort study that
included 108 patients evaluated at Mayo Clinic, Rochester,
Minnesota, between January 1980 and December 2014 was
performed. The longitudinal medical records of 1,515
patients were reviewed by a rheumatologist (FA-O). The
review included all patients with the diagnostic code of
polyarteritis nodosa (International Classification of Dis-
eases, Ninth Revision, code 446.0), as well as all patients
with the following key terms documented in their medical
records: medium vessel vasculitis, mesenteric vasculitis,
(localized) vasculitis of the GI tract, gallbladder vasculitis,
periarteritis nodosa, testicular vasculitis, cutaneous polyar-
teritis nodosa, cutaneous arteritis, limited polyarteritis
nodosa, PAN, and HBV-associated vasculitis. Confirmed GI
vasculitis cases previously reported by this group (10) and
additional cases identified over the extended study period
were included. Patients were classified according to the 1990
American College of Rheumatology (ACR) classification cri-
teria for PAN (11) and the 2012 International CHCC nomen-
clature to identify the appropriate vasculitis categories.
Patients diagnosed within 12 months of their first evaluation
at Mayo Clinic and having data related to first diagnosis were
included. Patients who had necrotizing vasculitis with pro-
teinase 3-ANCA or myeloperoxidase-ANCA positivity were
excluded. The study was approved by the Mayo Clinic Insti-
tutional Review Board.
Data collection. Data on demographics, clinical charac-
teristics, laboratory and imaging findings, treatment, and
outcomes were abstracted from medical records and docu-
mented in an electronic data-capture program (REDCap).
Definitions. Vasculitis on angiography. This was de-
fined as an arteriogram showing segmental narrowing, dila-
tation, occlusion, or aneurysms of visceral arteries (in the
absence of vessel changes of atherosclerosis or vasculitis
mimics such as fibromuscular dysplasia) and confirmation
by an expert radiologist that findings were consistent with
vasculitis.
PAN. The definition of PAN was based on the presence
of $3 of the 10 items of the 1990 ACR classification criteria
for PAN (11). Twenty-five of 48 patients with PAN also met
the CHCC 2012 histopathologic definition of “necrotizing
arteritis of medium or small arteries without glomerulone-
phritis or vasculitis in arterioles, capillaries, or venules and
not associated with ANCA” (1).
SOV. The definition of SOV was vasculitis in arteries or
veins of any size in a single organ, with no features to indi-
cate it as a manifestation of systemic vasculitis according to
the 2012 CHCC definition (1). Necrotizing vasculitis limited
to the GI system or typical angiographic findings in GI ves-
sels was classified as GI vasculitis. Necrotizing medium ves-
sel vasculitis limited to the skin was classified as CA.
Patients with isolated small vessel vasculitis in skin biopsies
were excluded.
Disease assessment. Disease activity. This was assessed
at all visits using the third version of the Birmingham Vascu-
litis Activity Score (BVAS), which rates 56 items derived
from evaluations in 9 systems or organ groups (12). Remis-
sion was defined as the absence of disease activity attribut-
able to vasculitis for $3 months (BVAS score 0). Relapse
was defined as the recurrence of vasculitic manifestations
(BVAS score .0), which required the addition of or a change
in treatment with immunosuppressive agents, the restart of
steroid treatment, and/or an increased steroid dose in a
patient following a $3 month period of clinical remission.
Failure was defined as the absence of clinical remission,
occurrence of new vasculitic manifestation(s), or death
before remission was achieved (13).
Prognosis. The prognostic Five-Factor Score (FFS), which
includes parameters predictive of poorer outcome and mor-
tality (creatinine .1.58 mg/dl, proteinuria .1 gm/24 hours,
GI involvement, cardiomyopathy, and central nervous sys-
tem involvement), was calculated at diagnosis (14).
Damage assessment. The Vasculitis Damage Index (VDI),
the only validated damage assessment measure for systemic
vasculitis, was used to determine the extent of vasculitis-
induced damage (15). For patients with followup, the VDI
score was calculated at the last visit.
Statistical analysis. Descriptive statistics (means, per-
centages, etc.) were used to summarize the data. Comparisons
between patients with different types of vasculitic involve-
ment (PAN, GI, and CA) were performed using chi-square
and Wilcoxon’s rank sum tests. Kaplan-Meier methods were
used to estimate survival rates and the cumulative incidence
of relapse in each group. Person-year calculations were used
to determine relapse rates for each group, allowing for multi-
ple relapses per patient. Rate ratios with 95% confidence
intervals (95% CIs) were calculated, assuming the occurrence
of relapses followed a Poisson distribution. Risk factors for
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mortality and first relapse were examined using univariable
Cox proportional hazards models. Statistical analyses were
performed using SAS, version 9.4, and R, version 3.1.1, statis-
tical packages.
RESULTS
Baseline characteristics. The study included 48 patients
with PAN, 41 patients with CA, and 19 patients with GI vas-
culitis. One patient did not fulfill the 1990 ACR criteria but
met the CHCC definition for PAN. This patient was included
in the PAN group based on expert opinion (study authors).
There was only 1 patient with CA whose disease activity
evolved into systemic PAN during the disease course. While
there was a male predominance in the PAN group, there
was female predominance in the CA and GI vasculitis
groups. The demographic and laboratory characteristics of
patients at diagnosis are presented in Table 1.
Most cases of PAN were idiopathic. Seven patients had
HBV surface antigen positivity, and 2 patients had hepatitis C
virus antibody (anti-HCV) positivity. Viral DNA was detected
in 5 of 7 patients with HBV positivity. Viral RNA was
detected in both patients with HCV positivity. Two patients
with PAN had a history of long-term minocycline use, which
was implicated as a potential etiologic factor for the develop-
ment of PAN. In the GI vasculitis group, 1 patient had HCV.
Four of 7 PAN patients with HBV positivity were treated
with antiviral agents together with immunosuppressive ther-
apy. Two patients did not receive antiviral treatment, due to
the absence of viremia. There were missing data regarding
HBV treatment for 1 patient. Two patients with PAN and 1
patient with GI vasculitis with HCV positivity were not
treated with antiviral agents during the course of this study.
At disease onset, the most common clinical features in the
PAN group were constitutional (n5 34, 71%), musculoskele-
tal (n 5 33, 69%), neurologic (n 5 27, 56%), and cutaneous
manifestations (n 5 27, 56%). Constitutional and musculo-
skeletal symptoms were less frequent in the CA and GI vascu-
litis groups. There was only 1 patient at baseline with
neurologic symptoms in the CA group, which manifested as
a nonvasculitic, sensory, peripheral neuropathy due to focal
nerve compression. The most common clinical feature in the
CA group was subcutaneous nodules (61%), while ischemic
abdominal pain was the predominant manifestation among
the GI vasculitis group (89%). The clinical manifestations of
all study patients are shown in Table 2.
A total of 43 tissue biopsy/resection samples were avail-
able for 35 patients in the PAN group: 21 skin, 7 surgically
resected bowel, 5 nerve, 3 renal, 2 temporal artery, 2 testicu-
lar, 1 muscle, 1 endomyocardial, and 1 sinus. Twenty-five of
these 35 patients with PAN had histologically proven necro-
tizing vasculitis involving medium-sized vessels. Five of 6
patients with surgically removed abdominal organ tissue
Table 1. Demographic and laboratory characteristics of patients with medium-sized vessel vasculitis at







(n 5 19) P
Demographics
Age at diagnosis, mean 6 SD years 52.8 6 15.8 49.1 6 18.8 52.6 6 15.7 0.65
Male, no. (%) 29 (60) 14 (34) 8 (42) 0.041†
Race, no. (%) 0.88
White 35 (95) 32 (91) 16 (94)
Black 0 (0) 1 (3) 0 (0)
Other 2 (6) 2 (6) 1 (6)
ACR criteria met, mean 6 SD 3.7 6 0.9 1.7 6 0.6 1.5 6 0.5 , 0.001†
Duration of symptoms, median (IQR) years 0.5 (0.2–1.4) 0.8 (0.3–1.7) 0.2 (0–1.9) 0.11
Laboratory parameters
White blood cell count (109/liter), median (IQR) 8.0 (6.2–15.9) 7.1 (5.3–10.6) 8.6 (6.0–12.3) 0.18
Hemoglobin, mean 6 SD gm/dl 12.5 6 2.1 12.8 6 1.8 13.0 6 1.7 0.56
Sedimentation rate, median (IQR) mm/hour 33.5 (9–80) 30.0 (12–49) 37.0 (10–53) 0.73
C-reactive protein, median (IQR) mg/liter 9.1 (3–26) 10.1 (2.9–33.1) 23.2 (7.5–83) 0.22
Proteinuria (.400 gm/24 hours) 5/44 (11) 1/35 (3) 1/16 (6) 0.35
Hematuria 1/44 (2) 0/35 (0) 1/15 (7) 0.32
Creatinine, mean 6 SD mg/dl 1.0 6 0.4 0.9 6 0.2 1.0 6 0.3 0.92
HBV positivity 7/46 (15) 0/36 (0) 0/17 (0) 0.013†
HCV positivity 2/45 (4) 0/34 (0) 1/16 (6) 0.40
Cryoglobulin positivity 1/33 (3) 0/29 (0) 0/11 (0) 0.54
Classic ANCA positivity 0/41 (0) 0/31 (0) 0/15 (0) –
Perinuclear ANCA positivity 7/41 (17) 3/31 (10) 0/15 (0) 0.19
MPO-ANCA 0/26 (0) 0/16 (0) 0/8 (0) –
PR3-ANCA 0/26 (0) 0/16 (0) 0/8 (0) –
* Values are the number/total number (%) unless otherwise indicated. PAN 5 polyarteritis nodosa; CA 5 cutaneous arteritis;
GI 5 gastrointestinal; ACR 5 American College of Rheumatology; IQR 5 interquartile range; HBV 5 hepatitis B virus;
HCV 5 hepatitis C virus; ANCA 5 antineutrophil cytoplasmic antibody; MPO 5 myeloperoxidase; PR3 5 proteinase 3.
† Statistically significant.
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samples in the GI vasculitis group and all 41 patients with
CA had histologically proven necrotizing vasculitis involv-
ing medium-sized vessels. Angiographic abnormalities were
present in 26 of 30 patients with PAN who had angiography,
and in 12 of 14 patients with GI vasculitis who had angiogra-
phy. All patients with abnormal angiograms in the GI vascu-
litis group and 81% in the PAN group demonstrated
irregular arterial stenoses. Microaneurysms were observed
in 75% of the GI vasculitis group and in 73% of the PAN
group. Pulse glucocorticoids (GCs) were given to 3 patients
(18%) with GI vasculitis and 7 patients (15%) with PAN.
Only 2 patients with PAN (4%) were treated with plasma-
pheresis. Forty-five patients (94%) with PAN, 38 patients
(93%) with CA, and 12 patients (67%) with GI vasculitis
were treated with oral GCs. The mean 6 SD initial oral GC
dose was 63.2 6 22.6 mg in the PAN group, 42.5 6 15.0 mg
in the CA group, and 61.7 6 10.3 mg in the GI vasculitis
group (P , 0.001). Additional immunosuppressive agents
were initiated at baseline in 32 PAN patients (67%), 7 GI
patients (37%), and 13 CA patients (32%) (P 5 0.002). Dap-
sone was used in 11 patients (27%) in the CA group. BVAS
scores were higher in patients with PAN than in those with
GI vasculitis or CA. The proportion of patients with FFS $1
was higher in the GI vasculitis group than in the PAN group
(58% versus 42%, respectively; P , 0.001) (Table 2).
Followup characteristics and relapses. Twenty-seven
patients with PAN, 18 patients with CA, and 9 patients with
GI vasculitis were followed for at least 6 months. Mean 6 SD
followup duration was 6.3 6 5.9 years in the PAN group,
6.8 6 6.8 years in the CA group, and 6.0 6 6.7 years in the GI
vasculitis group. Two patients in the PAN group and 3
Table 2. Baseline clinical characteristics of patients with medium-sized vessel vasculitis







(n 5 19) P
Constitutional symptoms 34/48 (71) 13/41 (32) 12/19 (63) 0.001†
Fever 12/48 (25) 8/41 (20) 3/19 (16) 0.66
Weight loss 22/48 (46) 2/40 (5) 8/19 (42) , 0.001†
Fatigue 27/44 (61) 10/41 (24) 4/18 (22) 0.001†
Musculoskeletal manifestations 33/48 (69) 22/41 (54) 2/19 (11) , 0.001†
Myalgia/weakness/leg tenderness 33/48 (69) 9/41 (22) 1/19 (5) , 0.001†
Arthralgia 15/47 (32) 17/41 (41) 2/19 (11) 0.057
Neurologic manifestations 27/48 (56) 1/41 (2) 0/19 (0) , 0.001†
Peripheral neuropathy 13/48 (27) 1/41 (2) 0/19 (0) , 0.001†
Mononeuritis multiplex 8/48 (17) 0/41 (0) 0/19 (0) 0.005†
Central nervous system involvement 6/48 (13) 0/41 (0) 0/19 (0) 0.019†
Testicular pain/tenderness (men only) 5/29 (17) 0/14 (0) 0/8 (0) 0.12
Recent-onset or severe hypertension 15/48 (31) 0/41 (0) 3/19 (16) , 0.001†
Cutaneous manifestations 27/48 (56) 41/41 (100) 0/19 (0) , 0.001†
Ulcers 6/48 (13) 6/41 (15) 0/19 (0) 0.22
Nodules 11/48 (23) 25/41 (61) 0/19 (0) , 0.001†
Purpura 13/48 (27) 13/41 (32) 0/19 (0) 0.023†
Livedo reticularis 13/48 (27) 16/41 (39) 0/19 (0) 0.007†
Peripheral extremity edema 9/47 (19) 5/39 (13) 0/19 (0) 0.12
GI manifestations 20/48 (42) 0/41 (0) 19/19 (100) , 0.001†
Abdominal pain 18/48 (38) 0/41 (0) 17/19 (89) , 0.001†
Bleeding (rectal or intraperitoneal) 5/48 (10) 0/41 (0) 6/19 (32) 0.001†
Cholecystitis 0/48 (0) 0/41 (0) 2/19 (11) 0.008†
Pancreatitis 0/48 (0) 0/41 (0) 1/18 (5) 0.094
GI manifestations requiring surgery 6/48 (13) 0/41 (0) 6/19 (32) 0.001†
Cardiac involvement 1/48 (2) 0/41 (0) 0/19 (0) 0.53
Vascular manifestations 3/48 (6) 0/41 (0) 0/19 (0) 0.145
Distal necrotic lesions 3/48 (6) 0/41 (0) 0/19 (0) 0.14
Ophthalmologic involvement 2/47 (4) 0/38 (0) 0/18 (0) 0.30
Pulmonary involvement 1/48 (2) 0/41 (0) 0/19 (0) 0.53
Pleural effusions 1/48 (2) 0/41 (0) 0/19 (0) 0.53
Ear/nose/throat involvement 1/44 (2) 0/41 (0) 0/19 (0) 0.50
FFS , 0.001†
0 28/48 (58) 41/41 (100) 8/19 (42)
1 17/48 (35) 0/41 (0) 11/19 (58)
$2 3/48 (6) 0/41 (0) 0/19 (0)
BVAS score at diagnosis, mean 6 SD 12.1 6 4.9 2.4 6 1.2 9.0 6 2.8 , 0.001†
* Values are the number/total number (%) unless otherwise indicated. PAN5 polyarteritis nodosa; CA 5 cutane-
ous arteritis; GI 5 gastrointestinal; FFS 5 Five Factor Score; BVAS 5 Birmingham Vasculitis Activity Score.
† Statistically significant.
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patients in the CA group never had clinical remission
throughout the followup period, in spite of different treat-
ment approaches. The 5-year cumulative rate of first relapse
was 45.2% in the CA group and only 9.6% in the PAN group
(Figure 1). During followup, there were 2 relapses in the PAN
group (1 minor and 1 major) and 10 minor relapses in the CA
group. The relapse rate was significantly higher in the CA
group compared to the PAN group (10.5 versus 1.2 per 100
person-years; rate ratio 7.15 [95% CI 2.20–45.16]). There
were no relapses in the GI vasculitis group during followup.
Patients with CA were not receiving GC treatment in 6 of
the 10 relapses. Five of 10 relapses in the CA group devel-
oped while patients were receiving immunosuppressive
therapy (2 methotrexate, 1 azathioprine, 1 mycophenolate
mofetil, and 1 sulfasalazine). One of 2 relapses in the PAN
group developed despite GC treatment. Patients with PAN
were not receiving additional immunosuppressives at the
time of relapse. Relapses were generally treated with an
increase in GC dose and/or a change in immunosuppressive
agent. The VDI score was comparable between the PAN and
GI vasculitis groups at the last followup, but was higher
than that of the CA group (P 5 0.030) (Table 3).
A total of 7 patients with PAN and 6 patients with GI vascu-
litis died during followup. The 1-, 5-, and 10-year survival
rates were 92.5%, 82.5%, and 66.2%, respectively, in the
PAN group and 60.6% at all 3 time points in the GI vasculitis
group (Figure 1). All deaths occurred within 1 year after diag-
nosis in the GI vasculitis group. Causes of death among the GI
patients were uncontrolled vasculitis (n 5 2), unknown
(n 5 2), cancer (n 5 1), and infection (n 5 1). Causes of death
among the PAN patients were cancer (n 5 2), uncontrolled
vasculitis (n 5 1), and unknown (n 5 4). There were no
deaths in the CA group during the followup.
Potential predictors of relapse and mortality were
assessed. The only characteristic significantly associated
with the development of the first relapse was CA diagnosis
(hazard ratio [HR] 5.07 [95% CI 1.02–25.18]). A lower BVAS
score at baseline was also significantly associated with the
development of the first relapse in a univariable model; how-
ever, it was no longer significant after adjustment for CA
diagnosis (P 5 0.19). Mortality was significantly associated
with older age (HR 1.05 [95% CI 1.01–1.09]), lower hemoglo-
bin level (HR 0.68 [95% CI 0.48–0.94]), weight loss (HR
13.79 [95% CI 2.99–63.69]), and arteriographic abnormalities
(HR 4.94 [95% CI 1.35–18.07]).
Further analysis was performed following the removal of
patients with positive hepatitis serologies from the PAN
group. With the exception of sex distribution no longer dem-
onstrating significance (P 5 0.20), due to 7 of the 9 patients
with hepatitis being male, no other changes were observed
in the comparison of baseline characteristics, initial treat-
ment, or outcome (data not shown).
DISCUSSION
PAN is a necrotizing, systemic medium vessel vasculitis,
typically without AAV and rarely affecting the lungs. These
distinctive characteristics differentiate PAN from other vas-
culitides. CA and localized GI vasculitis are less well under-
stood. While these conditions share similar histopathologic
findings with PAN, they appear to have distinct clinical
courses.
The pathogenesis of PAN remains unknown. However, in
a subset of patients, it may be associated with chronic HBV
infection. In this series, most cases of PAN were idiopathic.
There were 7 patients (15%) with HBV and 2 (4%) with HCV
in the PAN group. HBV-related PAN was reported in up to
35.3% of patients in a previous report (3). After successful
vaccination against HBV, the rate of HBV-related PAN has
decreased to less than 5% in developed countries (16).
Progression from CA to systemic PAN appears to be
exceedingly rare. There was only 1 patient in this cohort
whose CA evolved into systemic PAN during the disease
course. Analogous findings have been reported by Chen (6)
and Daoud et al (17), with the disease of 2 of 20 and 0 of 79
patients with CA, respectively, evolving into systemic PAN
during followup. There are scarce data regarding vasculitis
limited to the GI tract. In a report by Burke et al, the disease of
6 of 23 patients with isolated vasculitis of the GI tract pro-
gressed to systemic PAN during followup (18). In the present
study, there were no cases of progression from GI vasculitis to
PAN.
Musculoskeletal and constitutional symptoms were com-
mon in the current systemic PAN cohort, as in others (3,9).
Figure 1. A, Survival rate and B, cumulative rate of first relapse of
patients with medium-sized vessel vasculitis according to type of
vasculitic involvement: polyarteritis nodosa (solid line), cutaneous
arteritis (broken line), and gastrointestinal vasculitis (dotted line).
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Musculoskeletal symptoms (myalgia, arthralgia, leg tender-
ness) were also reported in more than half of patients with
CA. Symptoms among patients with CA, however, were lim-
ited to extremities affected by vasculitic lesions and often
secondary to reactive subcutaneous swelling and edema.
The underlying cause of constitutional symptoms among
patients with CA and GI vasculitis, as seen in this study and
others (9,18), is not fully understood. One possibility is the
systemic distribution of local inflammatory mediators lead-
ing to manifestations such as cytokine-associated fatigue.
Indeed, symptoms such as fatigue were reported by nearly a
quarter of patients with CA and GI vasculitis in this study.
In isolation, we could not use constitutional symptoms to
differentiate between a local versus a systemic process.
Neurologic manifestations are frequently detected in
systemic PAN. In the current series, 56% of patients with
PAN described neurologic symptoms at diagnosis, the
most common of which were peripheral neuropathy
(27%) and mononeuritis multiplex (17%). While mono-
neuritis multiplex is considered a direct consequence of
vasculitic neuropathy and a hallmark of underlying sys-
temic disease, the presence of isolated sensory peripheral
neuropathy is less specific. Indeed, studies have demon-
strated that 22–32% of patients with CA describe periph-
eral neuropathy at diagnosis without evidence of, or
progression to, systemic PAN (19,20). The etiology of such
symptoms is unknown but may result from peripheral
nerve compression due to extremity swelling as opposed
to vasculitic pathology. Such was the case with the single
patient in the CA group with mild sensory peripheral neu-
ropathic symptoms described herein.
PAN is generally considered to be a monophasic disease
with a low relapse rate, ranging from 10% in HBV-related
PAN (3) to 20–46% in idiopathic cases (3,9,21). Although
differences in clinical features and outcomes between
those with HBV-related disease and idiopathic PAN have
been observed, the low prevalence of HBV-related cases in
the present cohort prevented direct comparison. In the
current study, the 5-year cumulative relapse rate was only
9.6% in the PAN group. The 5-year cumulative relapse
rate was 45.2% in the CA group, which was significantly
higher than that in the PAN group. CA is a disease charac-
terized by a chronic, relapsing course (22). In the series
by Daoud et al, 9 of 39 patients with ulcerative CA still
had active cutaneous lesions after more than 10 years of
followup (17). No relapses were observed in the GI vascu-
litis group in the current study population.
The development of a first relapse was significantly
associated with a diagnosis of CA. While non-GC immu-
nosuppressive agents were used in 67% of patients with
PAN, only 32% of patients with CA received initial treat-
ment with immunosuppressive medications. Dapsone was
preferred by dermatologists in approximately one-fourth
of the CA patients in the current study. In routine practice,
oral GCs with or without topical treatments are widely
preferred by clinicians for patients with CA. There are few
small case series showing the efficacy of additional immu-
nosuppressive therapies such as methotrexate (23) and
Table 3. Treatment and damage assessment of patients with medium-sized vessel vasculitis






(n 5 9) P
Followup duration, mean 6 SD years 6.3 6 5.9 6.8 6 6.8 6.0 6 6.7 –
Treatment, ever
Oral glucocorticoids 27 (100) 15 (83) 8 (89) 0.10
Cyclophosphamide 11 (41) 0 2 (22) 0.007†
Methotrexate 1 (4) 4 (22) 2 (22) 0.13
Azathioprine 4 (15) 5 (28) 1 (11) 0.45
Mycophenolate mofetil 2 (7) 3 (17) 0 (0) 0.33
Treatment, last visit
Oral glucocorticoids 12 (44) 9 (50) 3 (33) 0.71
Prednisone dose, mean 6 SD mg 18.3 6 12.4 15.6 6 9.2 9.0 6 6.9 0.43
Other immunosuppressive agents 8 (30) 9 (50) 2 (22) 0.25
VDI score, median (IQR) 2 (1–3) 0 (0–2) 2 (0–3) 0.030†
VDI characteristics
Musculoskeletal 12 (44) 4 (22) 5 (56) 0.17
Skin/mucous membranes 2 (77) 4 (22) 0 (0) 0.15
Ocular 1 (4) 2 (11) 2 (22) 0.24
Cardiovascular 12 (44) 4 (22) 1 (11) 0.103
Peripheral vascular disease 6 (22) 2 (11) 0 (0) 0.23
Gastrointestinal 3 (11) 0 3 (33) 0.034†
Renal 6 (22) 0 2 (22) 0.096
Neuropsychiatric 4 (15) 2 (11) 0 (0) 0.47
Other 7 (26) 0 3 (33) 0.041†
* Values are the number (%) unless otherwise indicated. PAN 5 polyarteritis nodosa; CA 5 cutaneous arteritis;
GI 5 gastrointestinal; VDI 5 Vasculitis Damage Index; IQR 5 interquartile range.
† Statistically significant.
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intravenous immunoglobulin (24) in patients with cutane-
ous PAN resistant to high-dose GC treatment. Less intense
immunosuppressive therapy at diagnosis might be related
to the high relapse rate seen in patients with CA.
In this study, the 1-, 5-, and 10-year survival rates were
92.5%, 82.5%, and 66.2%, respectively, in PAN, which are
comparable to previous reports (3). The survival rate in the
first year after diagnosis was significantly lower in GI vascu-
litis than in PAN. In the series by Pagnoux et al, an FFS $1,
age .65 years, hypertension, and GI manifestations requir-
ing surgery were significantly associated with mortality (3).
Samson et al reported an excellent overall survival rate of
86% at 96 months in patients with PAN without poor prog-
nostic factors (FFS score 0) (25). No association between
FFS and mortality was detected in this patient population.
Mortality was significantly associated with older age, hemo-
globin level, weight loss, angiographic findings, and gastro-
intestinal and/or cutaneous manifestations. There is very
limited literature on vasculitis-related damage in PAN.
Samson et al evaluated damage in PAN using VDI scores.
The mean VDI score was 2.2, and the most frequent sequelae
were GC-related side effects, such as osteoporosis, cataracts,
and peripheral neuropathy (25). The VDI scores in the cur-
rent series were similar to the findings by Samson et al.
Hypertension and osteoporosis were the most frequent
items. As expected, in the present study, the VDI score was
comparable between the PAN and GI vasculitis groups, and
lower among patients with CA.
The major limitation of this study is inherent in its retro-
spective design. Data collection relies on documentation by
the treating physician at the time of clinical evaluation, which
was not standardized. The relatively small sample size, lack
of followup data on all patients, and relatively short-term fol-
lowup of patients are other significant limitations. Moreover,
there are no validated assessment tools that define clinical
activity, relapse, or remission in medium vessel vasculitis.
In conclusion, these results suggest that systemic PAN,
CA, and GI vasculitis have different clinical courses, which
suggests that they may be different conditions rather than
exist on the spectrum of a single disease. The progression of
CA to systemic PAN is very rare. Vasculitis-related damage is
comparable in PAN and GI vasculitis. The risk of relapse is
low in patients with PAN. Patients with CA have nearly a 5-
fold higher relapse rate than those with systemic PAN, possi-
bly due to less use of non-GC immunosuppressive agents.
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